A quiet rotation is turning into a broader uptrend across the
sector. ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏



 

[Morning Watchlist]

_You are receiving this email because you are subscribed to BEHIND THE
MARKETS. If you no longer wish to receive these emails,
please unsubscribe
[[link removed]] here._

_Prefer to view this content on our website? CLICK HERE.
[[link removed]]_

-------------------------

Dear Fellow Investor,

HEALTH CARE’S QUIET ROTATION IS BROADENING: 3 STOCKS POSITIONED TO
BENEFIT

Health care is quietly stepping back into the spotlight, and the most
interesting part is that it is not behaving like a purely defensive
trade.

Yes, health care has historically served as a steadier corner of the
market during periods of uncertainty. But the recent shift has a
different feel: the sector has flashed a rare historical signal, one
that has not appeared often over the last few decades. When this type
of setup has emerged in prior cycles, health care has often gone on to
deliver meaningful relative outperformance.

The second notable detail is _how_ the move has developed. For much of
the year, gains were concentrated in a relatively small cluster of
high-quality leaders, exactly the kind of narrow participation that
can make a sector rally look stronger than it really is. Narrow
leadership can persist, but it is also vulnerable: if the leaders
stall, the entire theme can fade quickly.

That is why the current phase matters. What began as a “stealth
rotation” is now broadening. More companies are joining the uptrend,
and investor attention is expanding from a handful of familiar winners
to a deeper bench across the industry. In market terms, improving
breadth is often what turns a short-lived move into a more durable
trend because it suggests the bid is not reliant on one or two names
carrying the whole group.

For long-term investors, this kind of broadening can be a meaningful
tell. When participation improves, it can indicate that the market is
starting to price in better fundamentals across the sector:
stabilizing demand, a more constructive earnings outlook, improving
visibility, or even a shift in how investors value cash flows. And in
health care specifically, broadening participation can also reflect a
rotation toward businesses with recurring demand drivers that are less
sensitive to the economic cycle.

With that backdrop, here is a look at three health care stocks that
appear well positioned to benefit from a stronger, broader sector tape
- supported by buy ratings from major firms and constructive implied
upside to price targets.

-------------------------

COMPANY: AGILENT TECHNOLOGIES (SYM: A)
PICKS-AND-SHOVELS EXPOSURE TO LIFE SCIENCES AND DIAGNOSTICS
RECENT PRICE: $141.74
PRICE TARGET: $168.08
FIRMS WITH BUY RATING: MORGAN STANLEY, GOLDMAN SACHS, UBS

Agilent operates as an applications-focused provider to the life
sciences, diagnostics, and applied chemical markets. Its business
spans three segments, Life Sciences and Applied Markets, Diagnostics
and Genomics, and Agilent CrossLab, giving it broad exposure to the
tools and services that support research, testing, and clinical
workflows.

From an investor perspective, Agilent is often viewed as a
“picks-and-shovels” way to participate in long-run health care and
biotech innovation. Instead of betting on the success of a single
drug, it sells essential instruments, consumables, and services that
are used across many customers and end markets. In many cycles, that
positioning can translate into a more resilient demand profile,
especially when the company has a meaningful installed base and
recurring service or consumables revenue.

Why might it benefit as the rotation broadens? When breadth improves
in health care, it is often because investors are looking beyond
headline drug makers and into the ecosystem that supports the entire
innovation pipeline. As confidence improves around research activity,
diagnostics demand, or clinical testing volumes, the market frequently
re-rates the enabling platforms that sit behind the scenes.

Analyst support from multiple major firms suggests confidence in the
company’s ability to execute through the next phase. The implied
upside to target also indicates that, even after recent strength in
parts of health care, some on the Street still see valuation room if
fundamentals and sentiment continue to firm.

What to watch into 2026: order trends, lab spending cycles, and
whether the mix continues to favor higher-value workflow solutions,
factors that can influence both growth and margin structure.

-------------------------

_Trading Whisperer_

WALL STREET’S NEW ETF TARGETS GLOBAL MONEY MOVEMENT
[[link removed]]

Money movement is changing faster than anyone expected.

Data centers run 24 hours. E-commerce runs 24 hours. Now finance is
racing to catch up.

A newly listed ETF just opened the door to that evolution, offering a
direct play on instant settlement through a simple, US listed wrapper.

Second-level finality. Institutional custody.

You trade it like any other fund. It reports like any other fund.

And while others chase hype, this product is built for discipline.
Single asset exposure, no leverage, no hidden overlays, and a clear
0.50% sponsor fee.*

Every previous digital-asset ETF proved the appetite. Strong volume.
Rapid AUM. A growing share of portfolios that used to avoid the space
entirely.

This one brings that same structure to the payments side, the part of
finance where efficiency actually pays.

The window to get in early is open. Learn more now.

GET THE SYMBOL BEFORE THE CROWD.
[[link removed]]

-------------------------

Company: ABBVIE (SYM: ABBV)
A SCALE BIOPHARMA STORY WITH MULTIPLE FRANCHISES
RECENT PRICE: $223.58
PRICE TARGET: $248.67
FIRMS WITH BUY RATING: HSBC, Piper Sandler, J.P. Morgan

AbbVie is a research-based biopharmaceutical company with a broad
global portfolio spanning immunology, oncology, neuroscience, eye
care, virology, and more. Investors most commonly associate AbbVie
with major immunology therapies, historically Humira and,
increasingly, newer therapies such as Skyrizi and Rinvoq, alongside a
wide set of other branded medicines and aesthetics products.

In a broadening health care tape, AbbVie can stand out for a different
reason than tools companies: it combines scale, cash flow, and
diversified end markets. When investors re-engage with health care
beyond the “defensive” framing, large, profitable biopharma
companies with multiple growth drivers and strong commercial execution
often re-enter the conversation as core holdings, not just tactical
positions.

The appeal is typically a blend of durability and optionality:

*
DURABILITY because demand for many therapies is not tightly linked to
GDP growth.

*
OPTIONALITY because successful drug franchises, label expansions, and
pipeline progress can create upside that is not always reflected in
near-term numbers.

Analyst buy ratings across multiple firms suggest a constructive
outlook on AbbVie’s ability to sustain performance as its portfolio
evolves. The gap between the recent price and target is not extreme,
but it still implies further upside if execution and earnings
visibility remain strong.

What to watch into 2026: continued performance across key franchises,
competitive dynamics in major therapeutic areas, and any pipeline
catalysts that could expand the company’s growth profile.

-------------------------

_Crypto 101_

GET IN BEFORE THE NEW YEAR RALLY HITS
[[link removed]]

Let me tell you something about memecoins...when they move, they move
FAST.

We're not talking about slow, steady 20% gains over months. We're
talking about:

→ 600% in a single day
→ 1,100% in 48 hours
→ 8,200% in 5 months

That's the kind of speed we've seen from my analysts Brian and Joe,
who have developed A SYSTEM FOR IDENTIFYING MEMECOINS BEFORE THEY
EXPLODE.
[[link removed]]

The market is oversold. Fear is everywhere. Most investors are sitting
on the sidelines waiting for "confirmation."

But January has historically been one of crypto's strongest months. A
new year rally could be building as we speak. And when momentum
returns to the market, memecoins don't just participate…they lead.

Brian and Joe just flagged their #1 MEMECOIN FOR JANUARY 2026.
[[link removed]]
It's still trading for pennies. It has viral energy, real utility, and
a capped supply with a burn mechanism built in.

You can get the full report—what the coin is, how to buy it, and
exactly what to expect—right now:

GET THE #1 MEMECOIN FOR JANUARY 2026 HERE
[[link removed]]

-------------------------

COMPANY: THERMO FISHER SCIENTIFIC (SYM: TMO)
A CATEGORY LEADER ACROSS THE LIFE SCIENCE STACK
RECENT PRICE: $567.36
PRICE TARGET: $631.80
FIRMS WITH BUY RATING: GOLDMAN SACHS, MORGAN STANLEY, BARCLAYS

Thermo Fisher is one of the most strategically important companies in
the life sciences ecosystem. It provides solutions across analytical
instruments, specialty diagnostics, lab products, and biopharma
services, selling everything from research consumables to
sophisticated instrumentation and services supporting drug development
and manufacturing.

Thermo Fisher’s breadth matters. In a sector rotation that is
broadening, businesses with multiple demand drivers can be especially
attractive because they are not dependent on one narrow pocket of the
industry. The company’s segments span research and discovery,
clinical and diagnostic testing, and bioproduction services, areas
that can take turns leading depending on the cycle.

Analysts who like Thermo Fisher often point to a few structural
strengths:

*
SCALE AND CUSTOMER REACH: It is embedded across pharma, biotech,
academia, government, and industrial markets.

*
RECURRING DEMAND: Many product categories are consumables- or
service-heavy, supporting repeat purchases.

*
STRATEGIC POSITIONING IN BIOPHARMA SERVICES: Outsourcing trends and
the complexity of biologics manufacturing can support long-run demand
for specialized capabilities.

The implied upside to the target suggests analysts see room for
appreciation if the market continues to reward health care
“infrastructure” businesses as the rotation widens.

What to watch into 2026: biopharma funding and production trends,
research activity levels, and how management balances growth and
margin priorities across segments.

-------------------------

_Paradigm Press_

THIS BACKDOOR PLAY ON STARLINK’S IPO FOR LESS THAN $100?
[[link removed]]
Whenever Elon Musk goes “all in” on something, it always generates
HUGE excitement and opportunity.
 
His latest project, Starlink – with its mission to provide satellite
Internet to every corner of the globe – is no exception.
 
And one man says it will soon go public, at an estimated $100 BILLION
valuation.
 
That would make it the biggest IPO in HISTORY…
 
Roughly 228X BIGGER than Amazon’s IPO.
 
Today, investing legend James Altucher has uncovered a smart,
unconventional way to potentially benefit from the impending Starlink
IPO…
 
This backdoor play lets savvy investors like you engage with
Starlink’s promise without the need for direct initial IPO access.

CLICK HERE TO LEARN HOW.
[[link removed]]

-------------------------

_What other stocks do you have your eye on heading into 2026? What
other sectors of the market are you currently interested in? Hit
"reply" to this email and let us know your thoughts!_

Examples that we provide of share price increases pertaining to a
particular Issuer from one referenced date to another represent an
arbitrarily chosen time period and are no indication whatsoever of
future stock prices for that Issuer and are of no predictive value.
Our stock profiles are intended to highlight certain companies for
YOUR further investigation; they are NOT stock recommendations or
constitute an offer or sale of the referenced securities.

We are issuing this disclosure in compliance with Section 17(b) of the
Securities Act, which requires us to disclose any compensation
received or expected to be received in cash or in kind in connection
with the purchase or sale of any security.

We would like to inform you that we have received or expect to receive
compensation in connection with the purchase or sale of the securities
of Canary XRP ETF (NASDAQ:XRPC). The compensation consists of up to
$6,500 and was received/will be received from Market Jar Media.

This communication should not be considered as an endorsement of the
securities of adviser Canary XRP ETF (NASDAQ:XRPC) and we are not
responsible for any errors or omissions in any information provided
about the securities of Canary XRP ETF (NASDAQ:XRPC) by Trading
Whisperer or Market Jar Media.

We encourage you to conduct your own due diligence and research before
making any investment decisions. You should also consult with a
financial advisor before making any investment decisions.

This disclosure is made as of 12/29/25.

*Brokerage commissions apply and will reduce returns

For standardized returns of the Canary XRP ETF, please visit [XRP ETF
- Canary Capital]. Past performance does not guarantee future results.

The Fund’s investment objectives, risks, charges and expenses should
be considered before investing. 

The prospectus contains this and other important information, and it
may be obtained at [link removed]. Read
it carefully before investing.
The Fund is not an investment company registered under the Investment
Company Act of 1940 (the “1940 Act”), and therefore is not subject
to the same regulatory requirements as mutual funds or traditional
ETFs registered under the 1940 Act.

Investing Involves Significant Risk. The loss of principal is
possible. Canary XRP ETF (the "Fund") may not be suitable for all
investors. This document does not constitute a recommendation of any
investment strategy or product for a particular investor. Investors
should consult a financial advisor/financial consultant before making
any investment decisions.

The fund is new with a limited operating history.

Digital assets, such as XRP, are a relatively new asset class, and the
market for digital assets is subject to rapid changes and uncertainty.
Digital assets are largely unregulated and digital asset investments
may be more susceptible to fraud and manipulation than more regulated
investments.

XRP is subject to unique and substantial risks, including significant
price volatility and lack of liquidity, and theft. The value of an
investment in the Fund could decline significantly and without
warning, including to zero. XRP is subject to rapid price swings,
including as a result of actions and statements by influencers and the
media, changes in the supply of and demand for digital assets, and
other factors. There is no assurance that XRP will maintain its value
over the long-term.  The Fund is not actively managed and will not
take any actions to take advantage, or mitigate the impacts, of
volatility in the price of XRP. An investment in the Fund is not a
direct investment in XRP. Investors will not have any rights that XRP
holders have and will not have the right to receive any redemption
proceeds in XRP. Shares of the Fund are generally bought and sold at
market price (not NAV) and are not individually redeemed from the
Fund. Only Authorized Participants may trade directly with the Fund
and only large blocks of Shares called "creation units." Your
brokerage commissions will reduce returns.

Paralel Distributors LLC serves as the marketing agent.  Paralel is
unaffiliated with Canary Capital and Native Ads.

Our mailing address is:
Behind the Markets, LLC
4260 NW 1st Avenue, Suite 55
Boca Raton, FL 33431

Copyright © 2024 Behind the Markets, LLC, All rights reserved.
You're receiving this email as part of your subscription to Behind the
Markets. For more information about our privacy practices, please
review our Privacy Policy
[[link removed]]
or our Legal Notices.
[[link removed]]

Behind the Markets
[[link removed]]

Unsubscribe
[[link removed]]

invisiblelink
[[link removed]]